At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Ixabepilone, Paclitaxel, and 2 other interventions for Breast Cancer. Completed, enrolled 384 participants across 49 sites in 15 countries.
Detailed Summary
The study will evaluate the effectiveness of ixabepilone when given after doxorubicin plus cyclophosphamide (AC) compared to standard treatment of paclitaxel given after doxorubicin plus cyclophosphamide in patients with early stage breast cancer. In addition the study will verify predefined biomarkers as well as discover new biomarkers that could identify patients who are more likely to respond to ixabepilone than standard paclitaxel based therapy.
Study Details
Timeline
Interventions
Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks
Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks
Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks
Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks